Advertisement
Advertisement


News

The Link Between Protease Inhibitors and Cancer

June 18, 2015

A large, multinational study published in JAIDS reports an increased risk of some cancers for people taking protease inhibitor-based combination antiretroviral therapy (PI-based cART) compared to non-nucleoside reverse transcriptase inhibitor-based cART (NNRTI-based cART). While any successful cART is known to decrease the risk of "AIDS-defining" cancers such as Kaposi sarcoma, the relationship between cART and other cancers has not been well understood.

The D:A:D study -- which included 41,762 participants with HIV from 11 cohorts across Europe, Australia and the United States -- investigated this issue. In this observational study, researchers collected information from participants about any non-AIDS related cancer experienced and antiretroviral treatments used between 2004 and 2012.

A total of 1,832 cancer diagnoses were included in the study: 718 were AIDS-defining cancers, while 1,114 were not. As expected, any type of cART use decreased risk of AIDS-defining cancers. But while use of NNRTI-based cART decreased risk of non-AIDS defining cancers too, exposure to protease inhibitor (PI)-based cART actually seemed to increase risk of non-AIDS defining cancers.

Advertisement
"Each additional year of exposure to NNRTI-based cART was associated with a 2% reduction in cancer risk. In contrast, each additional year of exposure to PI-based cART was associated with a 2% increase in cancer risk," explain Mathias Bruyand, MD, PhD and colleagues in the article.

This increased risk associated with PI use -- though small -- may compound and produce a noticeable clinical effect if cART is taken long-term. If there is a causal link between PIs and non-AIDS-defining cancer (which the prospective, observational nature of this study does not prove), the authors say exposure to PIs for five years could result in a 16% increased risk of developing a non-AIDS-defining cancer.

This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.




This article was provided by BETA. Visit their website at www.betablog.org.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.